Psychedelics Company Lands Deal To Dispense Ketamine Treatment Through 1,000+ Pharmacies In Canada

Champignon Brands announced this week that it will be dispensing its ketamine treatment through “one of Canada’s leading retail pharmacy chains.”

During an exclusive conversation, management said it cannot disclose the name of the pharmacy chain in question just yet. However, the team assures it is a company with a retail footprint of more than 1,000 stores in Canada.

The idea is to leverage the pharmacy chain’s infrastructure to help compound and distribute Champignon Brands’ ketamine prescriptions to a network of Canadian medical, pain and addiction clinics. The formulations will then be administered by these clinics, which will help the company gather data on the use of ketamine for the treatment of concussions, traumatic brain injury (TBI), anxiety, and treatment-resistant depression.

How It Works

When asked about the process, Champignon Brands explained that patients will need to see a participating doctor or specialist, such as an anxiety specialist, to get their ketamine treatment prescriptions.

Related story: COVID-19 And Mental Health: How To Get Ketamine-Based Psychedelic Therapy From Home Using An App

Once they get a prescription, they will be able to go to one of these pharmacies to fulfill them. They will receive a take-home cream, similar to a cream for eczema. Then, patients will be checking in with their doctors to talk about adverse side effects and/or results.

“We’re tremendously excited to begin dispensing our novel Ketamine topicals via this pharmacy location,” said Dr. Joseph Gabriel, Special Advisor to Champignon Brands and co-founder of LivRelief, explaining the program will be rolled out at one location first, with intentions to expand to others quickly. “This compounding and dispensing relationship will allow us to expedite our human chart reviews with various addiction and pain clinics.

“This relationship allows for future vertical integration and, once the Level B cleanroom is complete, our compounding capabilities will permit us to meet anticipated demand for our products.”

In addition to the above, Champignon announced this week that it has closed the acquisition of AltMed Capital, a Canada-based ketamine clinic operator and novel drug discovery company that runs a vertically-integrated, rapid-onset treatment center in Canada — operating from proof-of-concept to human clinical trials and publication.

Related story: Thiel Capital’s Jason Camm Discusses Joining Psychedelics Company ATAI Following $24 Million Raise

Stay tuned in for more news on psychedelics. More on the topic on El Planteo.